Microbial Contract Biomanufacturing Market is projected to be worth USD 9.3 billion by 2030, growing at a CAGR of 8.7%, claims Roots Analysis The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment London Roots Analysis has announced the addition of the “Microbial Contract Bio manufacturing Market, 2020-2030” report to its list of offerings. Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs. Get Detailed Report: https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
Topics
